Showing 463 results
-
Media Release /- My Home in Sight, developed in partnership with six leading patient advocacy organizations, provides five key principles of adapting spaces in the home to support those impacted by wet AMD and…
-
Media Release /Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5…
-
Media Release /- Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and…
-
Media Release /Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak First grants to focus on immediate need for digital tools and frontline medical…
-
Media Release /Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will be…
-
Media Release /- Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)1-…
-
Media Release /Wanda Sykes, Hailee Steinfeld, and Novartis—alongside national and local breast cancer advocacy groups—have joined forces to educate and motivate women across generations, body types, and…
-
Media Release /New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
-
Media Release /Novartis Pharmaceuticals Corporation (NPC) is aware of the recent Democratic Steering and Policy Committee session in the U.S. House of Representatives to discuss the Paycheck Fairness Act and…
-
Media Release /- ACZ885, which neutralizes key inflammatory driver interleukin-1 beta[1], provided significant symptom improvement vs. placebo in Phase III pivotal trial[2]- Systemic juvenile idiopathic arthritis…
